PROTECTOR is a multicentre, national prospective cohort surgical study for premenopausal women who are at increased risk of developing ovarian cancer either because of a genetic mutation (BRCA1/BRCA2/RAD51C/RAD51D/BRIP1) or a strong family history of ovarian and breast cancer or ovarian cancer alone. PROTECTOR has three arms: ‘risk reducing salpingo-oophorectomy’ (RRSO), ‘risk reducing early salpingectomy with delayed oophorectomy’ (RRESDO) and ‘controls’ (no surgery). Participants will be able to self-select which study arm they wish to participate in. The study is being co-ordinated from Barts Cancer Institute, Queen Mary University of London, and is funded by Barts and The London Charity and Rosetrees Trust.
The primary objective is to evaluate the impact on sexual function with RRESDO as a two-step ovarian cancer prevention strategy in premenopausal women at increased risk of ovarian cancer.
Approximately 30 hospitals across England, Wales, Scotland and Northern Ireland are recruiting participants for PROTECTOR. Our recruitment target is 1,000 participants (333 per study arm). If you would like to become a recruiting centre please contact our team. To enrol a patient into the PROTECTOR study, please refer to your nearest recruitment centre which can be found using our interactive map.